Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing.
The nearly $1 million grant will fund vaccine delivery research targeting infectious diseases and cancer EAST LANSING, Mich., March 14, 2022 -- Iaso Therapeutics, a research program focused on the [...]
Small Business Innovation Research Program Provides Seed Funding for R&D East Lansing, MI, 07/15/2021 – Iaso Therapeutics, INC. has been awarded a National Institute of Allergy and Infectious Diseases (NIAID) [...]
Vaccines have dominated the news. With the COVID-19 pandemic, stories about vaccines have been a daily occurrence. They range from concerns about safety to vaccination rates and distribution. They [...]
East Lansing, MI – Iaso Therapeutics (Iaso) has received a selective invitation to participate in the National Cancer Institute (NCI) Translational Resources to Expedite Commercialization Success Workshop (TRECS WORKSHOP). Iaso [...]
Craig Lyons Lansing State Journal LANSING – When Herbert Kavunja joined Iaso Therapeutics as its chief scientist and sole employee, he faced a steep learning curve. He had to figure [...]
Iaso Therapeutics received a Phase I SBIR grant from the National Cancer Institute (NCI). The grant is to study the feasibility of developing a cancer vaccine against breast cancer including [...]
Iaso Therapeutics received a Phase I SBIR grant from the National Science Foundation (NSF). The grant is to study the feasibility of commercializing Iaso’s mutant Qβ (mQβ) virus-like particle. The [...]
East Lansing, Michigan
rforgey@iasotherapeutics.com
773-437-0274
Copyright Iaso Therapeutics, Inc. | All Rights Reserved
Iaso appreciates support from the National Science Foundation
